Cargando…
PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429016/ http://dx.doi.org/10.1097/01.HS9.0000975848.41552.42 |
| _version_ | 1785090610159419392 |
|---|---|
| author | Cho, Seok-Goo Kim, Tae Min Taszner, Michał Chen, Tsai Yun Chaudhry, Aafia Ufkin, Melanie Uppala, Amulya Sabir, Ayesha Mohamed, Hesham Ambati, Srikanth Bachy, Emmanuel |
| author_facet | Cho, Seok-Goo Kim, Tae Min Taszner, Michał Chen, Tsai Yun Chaudhry, Aafia Ufkin, Melanie Uppala, Amulya Sabir, Ayesha Mohamed, Hesham Ambati, Srikanth Bachy, Emmanuel |
| author_sort | Cho, Seok-Goo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429016 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290162023-08-17 PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY Cho, Seok-Goo Kim, Tae Min Taszner, Michał Chen, Tsai Yun Chaudhry, Aafia Ufkin, Melanie Uppala, Amulya Sabir, Ayesha Mohamed, Hesham Ambati, Srikanth Bachy, Emmanuel Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429016/ http://dx.doi.org/10.1097/01.HS9.0000975848.41552.42 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Cho, Seok-Goo Kim, Tae Min Taszner, Michał Chen, Tsai Yun Chaudhry, Aafia Ufkin, Melanie Uppala, Amulya Sabir, Ayesha Mohamed, Hesham Ambati, Srikanth Bachy, Emmanuel PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title | PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title_full | PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title_fullStr | PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title_full_unstemmed | PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title_short | PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY |
| title_sort | pb2279: trial in progress: odronextamab, a cd20×cd3 bispecific antibody, for the treatment of patients with relapsed/refractory marginal zone lymphoma (mzl) – a cohort from the elm-2 study |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429016/ http://dx.doi.org/10.1097/01.HS9.0000975848.41552.42 |
| work_keys_str_mv | AT choseokgoo pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT kimtaemin pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT tasznermichał pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT chentsaiyun pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT chaudhryaafia pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT ufkinmelanie pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT uppalaamulya pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT sabirayesha pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT mohamedhesham pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT ambatisrikanth pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study AT bachyemmanuel pb2279trialinprogressodronextamabacd20cd3bispecificantibodyforthetreatmentofpatientswithrelapsedrefractorymarginalzonelymphomamzlacohortfromtheelm2study |